A Study of IBI3032 in Healthy Participants
A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBI3032 in Healthy Participants
Fortvita Biologics (USA)Inc.
32 participants
Sep 10, 2025
INTERVENTIONAL
Conditions
Summary
This is a randomized, double-blind, placebo-controlled Phase I clinical study evaluating the safety, tolerability, and PK of a single dose of IBI3032 in healthy participants. This is a single ascending dose (SAD) study. Approximately 32 healthy participants are expected to be enrolled in this study. The screening period is 4 weeks. Eligible participants will be divided into 4 cohorts. Each cohort consisted of 8 healthy participants who will be randomized in a 6:2 ratio to receive a single dose of IBI3032 or placebo. The safety follow-up period is 15 days. This study is for research purposes only, and is not intended to treat any medical condition.
Eligibility
Inclusion Criteria2
- Healthy male or females, as determined by medical history
- Have safety laboratory results within normal reference ranges
Exclusion Criteria3
- Have known allergies toIBI3032， glucagon-like peptide-1 (GLP-1) analogs, related compounds
- Abnormal electrocardiogram (ECG) at screening
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IBI3032: Method of administration: oral, fasted administration.
Placebo (without active ingredients) Method of administration: oral, fasted administration.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07120425